Infliximab and adalimumab, two immune checkpoint inhibitors that could blockade TNF, TNFRSF1A, and TNFRSF1B, were also included in the network, further highlighting the potential utilities in tumor immunotherapy of TNBC [51]. This evidence concerns the gene TNF and neoplasm.